<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04987242</url>
  </required_header>
  <id_info>
    <org_study_id>ALLN-346-201</org_study_id>
    <nct_id>NCT04987242</nct_id>
  </id_info>
  <brief_title>An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)</brief_title>
  <official_title>An Inpatient, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase IIa study is to evaluate the safety and tolerability of ALLN-346 in&#xD;
      subjects with hyperuricemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, 7-day, randomized, double-blind, placebo-controlled study of orally&#xD;
      administered ALLN-346 in subjects with hyperuricemia. Study will take place at a clinical&#xD;
      pharmacology unit (CPU). The study will have two Parts with Part 1 administering the target&#xD;
      dose and subject continuing Part 2 to explore a lower dose response.&#xD;
&#xD;
      The study will evaluate safety, tolerability, pharmacokinetics (lack of absorption) and&#xD;
      pharmacodynamics of ALLN-346.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2021</start_date>
  <completion_date type="Anticipated">February 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study population includes generally healthy subjects with hyperuricemia. The study is comprised of a planned Part 1, where the maximal tolerated dose from the MAD study in normal healthy volunteers (Study 102) will be administered, and an optional Part 2, which will explore a lower dose. If Part 2 is conducted, subjects from Part 1 will continue in Part 2 under the same treatment group (ALLN-346 or placebo). New subjects may enroll in Part 2 in the case where a Part 1 subject(s) does not continue.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Subjects, Investigators and laboratories involved in the conduct of the study will be blinded to subject treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>21 days per Study Part</time_frame>
    <description>Number of of participants with treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum ALLN-346</measure>
    <time_frame>8 days</time_frame>
    <description>Serum concentration of ALLN-346 (ng/mL)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum Urate</measure>
    <time_frame>8 days</time_frame>
    <description>Serum urate [mg/dL]</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hyperuricemia</condition>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>ALLN-346 (Engineered Urate Oxidase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALLN-346 is novel urate oxidase provided as capsules for oral administration. Two doses may be evaluated under two Study Parts: Part 1 (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days; Part 2 (3 capsules thrice daily (TID) for a total of 9 capsules per day) will be evaluated for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo capsules for oral administration. Two doses may be evaluated under two Study Parts: Part 1 (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days; Part 2 (3 capsules thrice daily (TID) for a total of 9 capsules per day) will be evaluated for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALLN-346</intervention_name>
    <description>ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration</description>
    <arm_group_label>ALLN-346 (Engineered Urate Oxidase)</arm_group_label>
    <other_name>Engineered urate oxidase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Matching placebo capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, age 18 to 55 years&#xD;
&#xD;
          -  sUA level â‰¥ 6.8 mg/dL at Screening (hyperuricemia), with or without a diagnosis of&#xD;
             gout&#xD;
&#xD;
          -  Not pregnant, not capable of pregnancy, not nursing, and agrees to use an effective&#xD;
             method of contraception; males subjects must agree to abstain from sperm donation&#xD;
&#xD;
          -  Normal non-clinically significant abnormalities in vital signs&#xD;
&#xD;
          -  Normal clinical laboratory test results and ECG, which are not considered to be&#xD;
             clinically significant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Screening eGFR of &lt;60 mL/minute/1.73 m2&#xD;
&#xD;
          -  History or clinical manifestations of significant metabolic, hematological, pulmonary,&#xD;
             cardiovascular, gastrointestinal, neurologic, hepatic, urological, or psychiatric&#xD;
             disorders.&#xD;
&#xD;
          -  Presence or history of any other condition (including surgery) known to interfere with&#xD;
             the absorption, distribution, metabolism, or excretion of medicines&#xD;
&#xD;
          -  Currently taking any urate-lowering medication within 4 weeks prior to Day 1 (first&#xD;
             dosing day)&#xD;
&#xD;
          -  Prior uricase therapy or exposure to recombinant uricase&#xD;
&#xD;
          -  Clinically significant abnormal findings on electrocardiogram (ECG)&#xD;
&#xD;
          -  Positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or&#xD;
             human immunodeficiency virus (HIV) antibody&#xD;
&#xD;
          -  Received treatment with or exposure to an Investigational drug or device within 30&#xD;
             days - prior to or during Screening&#xD;
&#xD;
          -  Prior dosing in ALLN-346 clinical study&#xD;
&#xD;
          -  Per Investigator judgment, is not an ideal clinical study candidate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C Tosone, MS, RAC</last_name>
    <role>Study Director</role>
    <affiliation>Allena Pharmceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>B Kandinov, PhD</last_name>
    <phone>(617) 467-4577</phone>
    <email>Clinical346@allenapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Armas, MD</last_name>
      <phone>602-437-0097</phone>
      <email>danielle.armas@celerion.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasburicase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

